Research Library · Comparative Guide
Hexarelin vs Ipamorelin: A Comparative Research Overview
For laboratory research use only. Not medical advice.
Overview
Two secretagogues, different profiles.
Hexarelin and Ipamorelin are both synthetic growth hormone secretagogues (GHS) that act on the ghrelin/GHS-R1a receptor to stimulate pulsatile GH release from the anterior pituitary. Despite the shared pathway, they diverge on potency, receptor selectivity, and downstream endocrine effects - differences that matter when designing in-vitro or animal-model research.
Mechanism of Action
Ghrelin-receptor agonism.
Hexarelin: a hexapeptide (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2) with high affinity for GHS-R1a and reported activity at the CD36 scavenger receptor in cardiac tissue in preclinical models.
Ipamorelin: a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) designed as a selective GHS-R1a agonist. Its structural profile minimizes cross-activation of receptors implicated in cortisol, prolactin, and ACTH release.
GH Release Profile
Amplitude vs selectivity.
Hexarelin produces one of the largest GH pulses of any GHS studied in preclinical literature. Tachyphylaxis has been reported with sustained dosing, and repeat exposure may attenuate response amplitude over time.
Ipamorelin produces a smaller, cleaner GH pulse without meaningful elevation of cortisol or prolactin in reported studies. Its shorter half-life and clean receptor profile make it a common reference agent for isolating GHS-R1a-specific effects.
Selectivity & Off-Target Effects
The cortisol / prolactin question.
Hexarelin's higher potency comes with reported off-target endocrine effects - modest elevations in cortisol and prolactin have been described in the literature. Ipamorelin is characterized as one of the most selective GHS-R1a agonists available for research, with no meaningful cortisol or prolactin response at typical experimental doses.
For research designs where isolating GH-axis signaling from HPA-axis activation is critical, Ipamorelin is often preferred. Where maximal GH amplitude is the endpoint under investigation, Hexarelin remains a common comparator.
Half-Life & Kinetics
Pulsatility windows.
Hexarelin - reported plasma half-life ~55 minutes in animal models; sustained receptor engagement contributes to tachyphylaxis risk with repeat administration.
Ipamorelin - reported plasma half-life ~2 hours in animal models; cleaner washout and preserved response with intermittent dosing.
At a Glance
Side-by-side summary.
| Attribute | Hexarelin | Ipamorelin |
|---|---|---|
| Class | Hexapeptide GHS | Pentapeptide GHS |
| GH Amplitude | High | Moderate |
| GHS-R1a Selectivity | Moderate | High |
| Cortisol / Prolactin | Modest elevation reported | Minimal reported |
| Tachyphylaxis | Reported | Less reported |
| Half-Life (animal) | ~55 min | ~2 h |
Research Framing
Choosing a comparator.
Selection between Hexarelin and Ipamorelin in a research protocol typically hinges on whether the study prioritizes GH-pulse magnitude (Hexarelin) or receptor-pathway selectivity with a clean endocrine background (Ipamorelin). Both compounds should be handled and stored per lyophilized peptide SOPs - reconstituted material refrigerated at 2-8°C and used within the storage window listed on each product page.
Research use only · Not for human consumption